Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Life science company RaQualia Pharma and Interprotein have entered into a collaborative research agreement to identify new drugs for a specific protein-protein interaction (PPI) in the disease domain of pain.
Subscribe to our email newsletter
The partnership will leverage RaQualia’s core expertise in drug discovery and development, and Interprotein’s platform technology, INTerprotein’s Engine for New Drug Design (INTENDD).
Under the agreement, RaQualia will provide Interprotein with upfront payment, contingency payment and further research milestones.
RaQualia said it will be eligible to receive the exclusive rights of all results from the collaborative research.
PPI, a biological responses produced by binding of two or more protein molecules, plays an important role in the pathophysiology of many diseases.